https://www.selleckchem.com/pr....oducts/D-Cycloserine
287; 95% CI 0.151-0.548; p less then 0.0001; median OS 9.1 vs 4.1 months). The incidence of adverse events in the glasdegib + LDAC arm decreased after 90 days' therapy 83.7% versus 98.7% during the first 90 days. Glasdegib + LDAC versus LDAC alone continued to demonstrate superior OS in patients with acute myeloid leukemia; the clinical benefit with glasdegib + LDAC was particularly prominent in patients with secondary acute myeloid leukemia. ClinicalTrials.gov identifier NCT01546038.Long-chain fatty acids (LCFAs) are a tremendous
Me gusta
Comentario
Compartir
